In Collaboration with Renowned Aesthetic Medicine Expert Dr. Jennifer Pearlman, Elevai's Study Will Investigate the Impact of Combining Exosome Skincare with Advanced Energy-Based Treatments for Optimal Skin Rejuvenation As the Global Energy-Based Aesthetic Device Market Is Projected to Reach $5.60 Billion by 2030, Elevai's Study Seeks to Unlock the Full Potential of Combining Exosome Skincare Products with These Technologies for Enhanced Facial Rejuvenation NEWPORT BEACH, Calif., Oct. 02, 2024 (GLOBE NEWSW ...

New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the "Offering") of approximately $8.0 million for its client Elevai Labs Inc. (NASDAQ: ELAB) (the "Company"), a pioneering force in medical aesthetics. The Offering was comprised of 28,571,425 shares of the Company's common stock (or pre-funded warrant ...

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a bestefforts offering, with no minimum amount of securities required to be sold. The offering is comprised of 2 ...

Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months. NEWPORT BEACH, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced positive case study results from patients undergoing laser therapy followed by use o ...

・ ® National Hair loss National Hair loss Medical Aesthetics Medical Aesthetics Education Course President Carly Klein | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------|---------|-------|-------|-------|-------|-------| | | | | | | | | | leading cause of | | | | | | | | Alopecia is Genetics | | | | | | | | While hair loss is a common affliction for both men and women, there are two underlying ...

On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes™. Ongoing Research to Combine Exosome and Mitochondrial Technology for Enhanced Scalp and Hair Vitality. NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced data results from an on-going research study conducted in partnership with Carly Klein, President of the National Hair Loss Medi ...

"One of the Biggest Innovations in Hair Loss We've Seen in Twenty-Five Years" - BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology1 Elevai Labs and Yuva Biosciences Join Forces for Breakthrough in Hair and Scalp Care Technology NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics announces the filing of two innovative patents in collaboration with Yuva Bioscien ...

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elev ...

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes ("ELEVAI exosomes™") contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix ("ECM"). ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data. Data implies ELEVAI exosomes™ may be ...

NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 Revenue increased to $605,529 for the three months ended June 30, 2024, and $1,220,092 for the six months ended June 30, 2024, an increase of 91.3% and 165.6% respectively year- ...